iBio, Inc. (IBIO)
USD 1.2
(-20.48%)
USD 1.2
(-20.48%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 | 225 Thousand USD | 0.0% |
| 2023 | - USD | -100.0% |
| 2022 | 2.38 Million USD | 0.51% |
| 2021 | 2.37 Million USD | 44.75% |
| 2020 | 1.63 Million USD | -18.83% |
| 2019 | 2.01 Million USD | 354.5% |
| 2018 | 444 Thousand USD | 12.69% |
| 2017 | 394 Thousand USD | -58.44% |
| 2016 | 948 Thousand USD | -48.78% |
| 2015 | 1.85 Million USD | 802.93% |
| 2014 | 205 Thousand USD | -79.64% |
| 2013 | 1 Million USD | -21.16% |
| 2012 | 1.27 Million USD | 145.61% |
| 2011 | 520.08 Thousand USD | 0.0% |
| 2010 | - USD | -100.0% |
| 2009 | 1.17 Million USD | 19.2% |
| 2008 | 987.05 Thousand USD | 10.13% |
| 2007 | 896.27 Thousand USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 FY | 225 Thousand USD | 0.0% |
| 2024 Q2 | - USD | -100.0% |
| 2024 Q3 | - USD | 0.0% |
| 2024 Q4 | 175 Thousand USD | 0.0% |
| 2024 Q1 | 50 Thousand USD | 0.0% |
| 2023 Q4 | - USD | 0.0% |
| 2023 Q1 | - USD | -100.0% |
| 2023 Q3 | - USD | 0.0% |
| 2023 Q2 | - USD | 0.0% |
| 2023 FY | - USD | -100.0% |
| 2022 Q2 | 168 Thousand USD | -20.38% |
| 2022 FY | 2.38 Million USD | 0.51% |
| 2022 Q4 | 61 Thousand USD | -96.86% |
| 2022 Q1 | 211 Thousand USD | -57.03% |
| 2022 Q3 | 1.94 Million USD | 1056.55% |
| 2021 Q3 | 765 Thousand USD | 8.51% |
| 2021 FY | 2.37 Million USD | 44.75% |
| 2021 Q2 | 705 Thousand USD | 71.95% |
| 2021 Q4 | 491 Thousand USD | -35.82% |
| 2021 Q1 | 410 Thousand USD | -63.39% |
| 2020 Q2 | 314 Thousand USD | 190.74% |
| 2020 FY | 1.63 Million USD | -18.83% |
| 2020 Q4 | 1.12 Million USD | 1066.67% |
| 2020 Q1 | 108 Thousand USD | -86.42% |
| 2020 Q3 | 96 Thousand USD | -69.43% |
| 2019 FY | 2.01 Million USD | 354.5% |
| 2019 Q1 | 45 Thousand USD | -50.55% |
| 2019 Q2 | 651 Thousand USD | 1346.67% |
| 2019 Q3 | 527 Thousand USD | -19.05% |
| 2019 Q4 | 795 Thousand USD | 50.85% |
| 2018 Q3 | 78 Thousand USD | -49.02% |
| 2018 Q2 | 153 Thousand USD | 25.41% |
| 2018 Q4 | 91 Thousand USD | 16.67% |
| 2018 Q1 | 122 Thousand USD | -17.01% |
| 2018 FY | 444 Thousand USD | 12.69% |
| 2017 Q1 | 135 Thousand USD | -50.91% |
| 2017 Q4 | 147 Thousand USD | 297.3% |
| 2017 Q3 | 37 Thousand USD | -50.67% |
| 2017 Q2 | 75 Thousand USD | -44.44% |
| 2017 FY | 394 Thousand USD | -58.44% |
| 2016 Q4 | 275 Thousand USD | -27.44% |
| 2016 Q1 | 160 Thousand USD | -49.37% |
| 2016 Q2 | 134 Thousand USD | -16.25% |
| 2016 FY | 948 Thousand USD | -48.78% |
| 2016 Q3 | 379 Thousand USD | 182.84% |
| 2015 Q4 | 316 Thousand USD | -9.46% |
| 2015 FY | 1.85 Million USD | 802.93% |
| 2015 Q3 | 349 Thousand USD | -4.9% |
| 2015 Q2 | 367 Thousand USD | -55.19% |
| 2015 Q1 | 819 Thousand USD | 299.51% |
| 2014 Q1 | - USD | -100.0% |
| 2014 FY | 205 Thousand USD | -79.64% |
| 2014 Q4 | 205 Thousand USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q2 | - USD | -100.0% |
| 2013 Q1 | 390.18 Thousand USD | 11.03% |
| 2013 FY | 1 Million USD | -21.16% |
| 2013 Q4 | 616.81 Thousand USD | 0.0% |
| 2012 FY | 1.27 Million USD | 145.61% |
| 2012 Q4 | 351.41 Thousand USD | -5.47% |
| 2012 Q1 | 320.34 Thousand USD | -6.9% |
| 2012 Q2 | 233.83 Thousand USD | -27.01% |
| 2012 Q3 | 371.75 Thousand USD | 58.98% |
| 2011 Q1 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q3 | 175.99 Thousand USD | 0.0% |
| 2011 Q4 | 344.08 Thousand USD | 95.51% |
| 2011 FY | 520.08 Thousand USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q1 | - USD | -100.0% |
| 2010 FY | - USD | -100.0% |
| 2009 Q1 | 333.42 Thousand USD | 257.74% |
| 2009 FY | 1.17 Million USD | 19.2% |
| 2009 Q4 | 137.15 Thousand USD | -58.04% |
| 2009 Q3 | 326.88 Thousand USD | -13.78% |
| 2009 Q2 | 379.13 Thousand USD | 13.71% |
| 2008 Q1 | 239.59 Thousand USD | 0.0% |
| 2008 Q4 | 93.2 Thousand USD | -77.49% |
| 2008 Q2 | 240.22 Thousand USD | 0.26% |
| 2008 FY | 987.05 Thousand USD | 10.13% |
| 2008 Q3 | 414.03 Thousand USD | 72.36% |
| 2007 FY | 896.27 Thousand USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 202 Thousand USD | -11.386% |
| Ampio Pharmaceuticals, Inc. | - USD | -Infinity% |
| Armata Pharmaceuticals, Inc. | 4.52 Million USD | 95.032% |
| Actinium Pharmaceuticals, Inc. | 81 Thousand USD | -177.778% |
| Azitra, Inc. | 686 Thousand USD | 67.201% |
| Can-Fite BioPharma Ltd. | 743 Thousand USD | 69.717% |
| Chromocell Therapeutics Corporation | - USD | -Infinity% |
| Calidi Biotherapeutics, Inc. | - USD | -Infinity% |
| CEL-SCI Corporation | - USD | -Infinity% |
| Lineage Cell Therapeutics, Inc. | 8.94 Million USD | 97.485% |
| MAIA Biotechnology, Inc. | - USD | -Infinity% |
| Matinas BioPharma Holdings, Inc. | 1.09 Million USD | 79.471% |
| Navidea Biopharmaceuticals, Inc. | 65.65 Thousand USD | -242.716% |
| NovaBay Pharmaceuticals, Inc. | 14.72 Million USD | 98.472% |
| NanoViricides, Inc. | - USD | -Infinity% |
| Oragenics, Inc. | 37.65 Thousand USD | -497.562% |
| BiomX Inc. | -357 Thousand USD | 163.025% |
| BiomX Inc. | -357 Thousand USD | 163.025% |
| Protalix BioTherapeutics, Inc. | 65.49 Million USD | 99.656% |
| Palatin Technologies, Inc. | 4.49 Million USD | 94.989% |
| Scorpius Holdings, Inc. | 6.99 Million USD | 96.783% |
| Theriva Biologics, Inc. | - USD | -Infinity% |